tetano
Editor, Senior Moderator
World J Virol
. 2024 Mar 25;13(1):88660.
doi: 10.5501/wjv.v13.i1.88660. Efficacy and safety of bamlanivimab in patients with COVID-19: A systematic review and meta-analysis
Behnam Amani[SUP] 1 [/SUP], Lida Khodavirdilou[SUP] 2 [/SUP], Kourosh Rajabkhah[SUP] 3 [/SUP], Vida Kardan Moghaddam[SUP] 4 [/SUP], Arash Akbarzadeh[SUP] 5 [/SUP], Bahman Amani[SUP] 6 [/SUP]
Affiliations
Background: Monoclonal antibodies (mAbs) have shown clinical benefits against coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Several studies have reported the use of bamlanivimab as a promising treatment option for COVID-19.
Aim: To synthesize the latest evidence for the efficacy and safety of bamlanivimab alone in the treatment of adult patients with COVID-19.
Methods: A literature search was conducted in PubMed, Cochrane Library, Web of Science, medRxiv, and Google Scholar using "SARS-CoV-2", "COVID-19", "LY-CoV555", and "Bamlanivimab" keywords up to January 25, 2023. The quality of included studies was assessed using the Cochrane bias tools. The Comprehensive Meta-Analysis software version 3.0 was used to analyze the data.
Results: A total of 30 studies involving 47368 patients were included. A significant difference was observed between the bamlanivimab and standard of care/placebo groups in terms of mortality rate [risk ratio (RR) = 50, 95% confidence interval (CI): 0.36-0.70], hospitalization rate (RR = 0.51; 95%CI: 0.39-0.68), and emergency department (ED) visits (RR = 0.69; 95%CI: 0.47-0.99); while the two groups exhibited no significant difference in terms of intensive care unit (ICU) admission (P > 0.05). Compared to other mAbs, bamlanivimab was associated with a higher rate of hospitalization (RR = 1.44; 95%CI: 1.07-1.94). However, no significant difference was detected between the bamlanivimab and other mAbs groups in terms of mortality rate, ICU admission, and ED (P > 0.05). The incidence of any adverse events was similar between the bamlanivimab and control groups (P > 0.05).
Conclusion: Although the results suggest the efficacy and safety of bamlanivimab in COVID-19 patients, further research is required to confirm the efficacy of this drug for the current circulating SARS-CoV-2 variants.
Keywords: Bamlanivimab; COVID-19; Meta-analysis; Monoclonal antibody; SARS-CoV-2.
. 2024 Mar 25;13(1):88660.
doi: 10.5501/wjv.v13.i1.88660. Efficacy and safety of bamlanivimab in patients with COVID-19: A systematic review and meta-analysis
Behnam Amani[SUP] 1 [/SUP], Lida Khodavirdilou[SUP] 2 [/SUP], Kourosh Rajabkhah[SUP] 3 [/SUP], Vida Kardan Moghaddam[SUP] 4 [/SUP], Arash Akbarzadeh[SUP] 5 [/SUP], Bahman Amani[SUP] 6 [/SUP]
Affiliations
- PMID: 38616851
- PMCID: PMC11008398
- DOI: 10.5501/wjv.v13.i1.88660
Background: Monoclonal antibodies (mAbs) have shown clinical benefits against coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Several studies have reported the use of bamlanivimab as a promising treatment option for COVID-19.
Aim: To synthesize the latest evidence for the efficacy and safety of bamlanivimab alone in the treatment of adult patients with COVID-19.
Methods: A literature search was conducted in PubMed, Cochrane Library, Web of Science, medRxiv, and Google Scholar using "SARS-CoV-2", "COVID-19", "LY-CoV555", and "Bamlanivimab" keywords up to January 25, 2023. The quality of included studies was assessed using the Cochrane bias tools. The Comprehensive Meta-Analysis software version 3.0 was used to analyze the data.
Results: A total of 30 studies involving 47368 patients were included. A significant difference was observed between the bamlanivimab and standard of care/placebo groups in terms of mortality rate [risk ratio (RR) = 50, 95% confidence interval (CI): 0.36-0.70], hospitalization rate (RR = 0.51; 95%CI: 0.39-0.68), and emergency department (ED) visits (RR = 0.69; 95%CI: 0.47-0.99); while the two groups exhibited no significant difference in terms of intensive care unit (ICU) admission (P > 0.05). Compared to other mAbs, bamlanivimab was associated with a higher rate of hospitalization (RR = 1.44; 95%CI: 1.07-1.94). However, no significant difference was detected between the bamlanivimab and other mAbs groups in terms of mortality rate, ICU admission, and ED (P > 0.05). The incidence of any adverse events was similar between the bamlanivimab and control groups (P > 0.05).
Conclusion: Although the results suggest the efficacy and safety of bamlanivimab in COVID-19 patients, further research is required to confirm the efficacy of this drug for the current circulating SARS-CoV-2 variants.
Keywords: Bamlanivimab; COVID-19; Meta-analysis; Monoclonal antibody; SARS-CoV-2.